MOLECULAR MARKERS OF EARLY CERVICAL NEOPLASIA

Area of Science:

• Cervical Pathology
• Histopathology
• Biomarker Discovery

Background:

• Distinguishing high-grade squamous intraepithelial lesions (HSILs) from mimics is diagnostically challenging.
• Nonconventional HSILs, including those with metaplastic phenotypes or overlapping features with adenocarcinoma in situ (SMILE), complicate accurate classification.
• Existing diagnostic methods rely heavily on morphology, leading to potential variability.

Purpose of the Study:

• To evaluate the utility of biomarkers in improving the diagnostic accuracy of HSILs.
• To explore how gene expression and protein profiling can reduce diagnostic variability in cervical pathology.
• To assess the role of specific biomarkers in differentiating HSILs from benign proliferations.

Main Methods:

• Review of gene expression and protein profiling studies for HSIL detection.
• Analysis of the clinical utility of biomarkers such as p16(INK4A) and MIB-1.
• Comparison of biomarker performance in differentiating squamous intraepithelial lesions (SILs) from normal, atrophic, or reactive epithelium.

Main Results:

• Biomarkers p16(INK4A) and MIB-1 are clinically useful for HSIL detection, complementing each other.
• p16(INK4A) and MIB-1 effectively differentiate SILs from normal/atrophic (MIB-1 low) or reactive/immature metaplastic (p16(INK4A) scattered) epithelium.
• Biomarkers are most valuable in distinguishing benign immature or atrophic proliferations from HSIL.

Conclusions:

• Biomarker analysis, particularly using p16(INK4A) and MIB-1, enhances the specificity of histological and cytological analysis for HSIL.
• These biomarkers aid in reducing diagnostic variability, especially when distinguishing HSIL from mimics.
• Careful morphological assessment on H&E sections remains crucial for differentiating low-grade SIL (LSIL) from HSIL, given the clinical implications.